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As a prototype of the TGF-β superfamily cytokines, TGF-β is well known for its diverse roles in embryogenesis and adult tis-
sue homeostasis. TGF-β evokes cellular responses by signaling mainly through cell membrane receptors and transcription fac-
tor R-Smads and Co-Smad (Smad4), while an inhibitory Smad, Smad7, acts as a critical negative regulator of TGF-β signaling. 
Smad7 antagonizes TGF-β signaling by regulating the stability or activity of the receptors or blocking the DNA binding of the 
functional R-Smad-Smad4 complex in the nucleus. However, the function of Smad7 in the nucleus is not fully understood. Yin 
Yang 1 (YY1) is a ubiquitously expressed transcription factor with multiple functions. It has been reported that YY1 can inhib-
it Smad-dependent transcriptional responses and TGF-β/BMP-induced cell differentiation independently of its DNA binding 
ability. In this study, we found that Smad7 interacts with YY1 and the interaction is attenuated by TGF-β signaling. Reporter 
assays and target gene expression analyses revealed that Smad7 and YY1 act in concert to inhibit TGF-β-induced transcription 
in the nucleus. Furthermore, Smad7 could enhance the interaction of YY1 with the histone deacetylase HDAC1. Consistently, 
YY1 and HDAC1 augmented the transcription repression activity of Smad7 in Gal4-luciferase reporter analysis. Therefore, our 
findings define a novel mechanism of Smad7 and YY1 to antagonize TGF-β signaling. 
TGF-β, Smad7, YY1, HDAC1, signaling regulation, transcriptional co-repressor 
 
Citation:  Yan XH, Pan J, Xiong WW, Cheng MZ, Sun YY, Zhang SP, Chen YG. Yin Yang 1 (YY1) synergizes with Smad7 to inhibit TGF-β signaling in the 




TGF-β (transforming growth factor-beta) is a prototype of 
the large TGF-β cytokine superfamily, which comprises 33 
members in mammalian cells, including TGF-β, activin, 
nodal, BMPs (bone morphogenetic proteins), GDFs (growth 
differentiation factors) and others [14]. Since its first dis-
covery in the early 1980s, TGF-β has attracted much atten-
tion due to its diverse roles in regulating cellular activities, 
such as cell proliferation and differentiation, apoptosis and 
senescense, cell matrix remodeling, adhesion and migration 
[57]. It is well established that TGF-β is a critical player in 
embryogenesis and adult tissue homeostasis. To achieve this, 
TGF-β signal transduction is finely controlled tempo-  
spatially via multiple mechanisms, and dysregulation of 
TGF-β signaling is closely associated with a wide array of 
human disorders including tumorigenesis, tissue fibrogene-
sis and developmental defects [2,810]. 
TGF-β signaling is initiated when the ligands bind to 
their cognate cell membrane serine/threonine kinase recep-
tors, the type II TGF-β receptor TβRII and the type I recep-
tor TβRI, where TβRI is phosphorylated and activated by 
TβRII [4,11]. Then signaling is propagated to downstream 
Smad proteins, although some other signaling molecules 
(MAPKs, PI3K/Akt, PAK2, RhoA, LIMK1/2, etc.) are also 
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reported to be activated by TGF-β in different circumstanc-
es or cell types [12]. The Smad protein family members are 
divided into three groups based on their structures and func-
tions. Upon TGF-β stimulation, R -Smads (receptor-  
regulated Smads, Smad2/3 for TGF-β) are phosphorylated 
directly by TβRI at the carboxyl terminal SXS motif, oli-
gomerize with Co-Smad (common Smad, Smad4) and ac-
cumulate together in the nucleus, where they bind DNA and 
regulate target gene expression in collaboration with other 
transcription factors or co-factors [11,13].  
Smad6 and Smad7 constitute the third group of the Smad 
family, I-Smads (inhibitory Smads), functioning as critical 
negative regulators of the TGF-β superfamily signaling 
[14,15]. They share conserved C-terminal MH2 domains 
with R-Smads and Smad4, but the N-terminal domains are 
more divergent. Gene targeting and transgenic studies in 
mouse models clearly affirmed the significant roles of 
Smad7 in embryonic development, tissue maintenance and 
disease progression [1518]. Biochemical studies revealed 
that multiple mechanisms can be exploited by Smad7 to 
inhibit TGF-β signaling. In the cytoplasm, Smad7 forms a 
complex with TGF-β receptors and recruits E3 ubiquitin 
ligases, phosphatases and other regulators, thus affecting 
receptor stability or activity [2,14,19]. We have reported 
that in the nucleus, Smad7 can bind DNA in a sequence- 
specific manner and inhibit TGF-β signaling by impeding 
functional Smad-DNA complex formation [20,21]. Smad7 
also interacts with histone deacetylases (HDACs), E2F1 and 
SIRT1, implying that Smad7 might act as a transcriptional 
repressor/co-repressor and regulate gene expression epige-
netically [2224]. Interestingly, Smad7 can also associate 
with the transcription factor IRF1 or MyoD, and behave as a 
co-activator [25,26]. Similarly, Smad6 acts as a co-repressor 
by associating with HDACs, Hoxc-8 or CtBP in the BMP 
pathways [2729]. In addition to Smad6/7, HDACs can also 
interact with and be recruited by other Smad proteins, me-
diating Smad-induced transcriptional repression [13]. 
Yin Yang 1 (YY1) is a multifaceted nuclear protein first 
cloned and characterized in 1991 [3032]. Early studies 
indicated that YY1 is a ubiquitously expressed and evolu-
tionarily conserved transcription factor, containing four 
C2H2-type zinc fingers at the C-terminus and histi-
dine/acidic amino acid-rich regions at the N-terminus. The 
zinc fingers mediate specific DNA binding, while both of 
the N- and C-terminal domains are required for its tran-
scriptional activities. As the name implies, YY1 can either 
activate or repress gene expression, depending on associated 
proteins and/or cell types. Several histone modifiers have 
been documented to associate with YY1. Recruitment of 
co-activators p300, CBP, PCAF or PRMT1 could lead to 
target gene activation via histone modifications, while re-
cruitment of co-repressors HDACs, Ezh1/2 or DNMTs 
would result in histone deacetylation, H3K27 methylation 
or promoter hypermethylation, and finally gene suppression.  
In addition, several recent studies showed that YY1 may 
affect gene expression independently of its DNA binding 
ability. YY1 associates with androgen receptor (AR) and 
stimulates the expression of prostate-specific antigen (PSA) 
in prostate cancer cells, and a YY1 mutant deficient in DNA 
binding is similarly effective [33]; in addition, YY1 acts as 
a co-repressor for the transcription factor HOXA11, 
GON4L and ATF/CREB [3436]. Likewise, YY1 interacts 
with R-Smads (Smad1/2/3) and Smad4, inhibiting Smad- 
mediated transcriptional responses by disrupting Smad- 
DNA binding, thus interfering with TGF-β/BMP- stimulat-
ed cell differentiation; all of these effects do not depend on 
the DNA binding activity of YY1 [37]. YY1 was also 
shown to work with Smad1/4 in BMP-induced heart-   
specific expression of CAR3 in chicks [38]. However, the 
interplays between YY1 and the TGF-β/BMP pathways are 
not fully understood.  
Although the nuclear functions of Smad7 have been ex-
emplified by several studies, the underlying mechanisms 
and regulatory mechanisms remain elusive. In this study, we 
characterized the interaction between Smad7 (also Smad6) 
and YY1, which could be attenuated by TGF-β signaling. 
Reporter assay and in vivo target gene expression analyses 
revealed that YY1 and Smad7 cooperate with one another to 
inhibit TGF-β/Smad-driven transcription, while knockdown 
of endogenous YY1 or Smad7 attenuates the inhibitory ef-
fects of the other protein. Mechanistically, Smad7 is capable 
of promoting the YY1-HDAC1 association in the nucleus, 
consistent with that YY1 and HDAC1 facilitate the tran-
scription repression activity of Smad7 in Gal4-luciferase 
reporter assay. Together, these results define a novel mech-
anism for TGF-β signaling regulation.  
1  Materials and methods 
1.1  Cell culture and transfection 
Human embryonic kidney (HEK) 293T cells, 293FT cells 
and Hep3B hepatocellular carcinoma cells were grown in 
DMEM (Dulbecco’s Modified Eagle Media) supplemented 
with 10% fetal bovine serum (FBS) at 37°C in a humidified, 
5% CO2 incubator. Transfection was accomplished with 
VigoFect (Vigorous Biotechnology, Beijing, China) or 
Lipofectamine 2000 (Invitrogen, USA) according to the 
manufacturer’s instructions. 
1.2  Plasmids and antibodies 
YY1 constructs were generously provided by Dr. Shi Yang 
(Harvard Medical School, USA) and Gal4-TK-luciferase 
reporter was a gift from Dr. Feng XinHua (Baylor College 
of Medicine, USA). The HDAC1 coding sequence was 
cloned into pcDNA3; Gal4-DBD (DNA binding do-
main)-fused Smad7 construct was generated based on 
pcDNA3.1+, and other protein-coding constructs and Smad7 
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shRNA plasmid were described previously [20,39,40]. 
siRNAs targeting human YY1 were designed as GGGAG-
CAGAAGCAGGUGCAGAUdTdT, GCAAGAAGAGUU- 
ACCUCAGdTdT and GGCAGAAUUUGCUAGAAUG-
dTdT for siRNA 1 to 3, respectively. Smad7 antibody was 
generated by immunizing rabbits with the N-terminal do-
main of Smad7 (amino acids (aa) 1259). Anti-Flag anti-
body (M2) was purchased from Sigma (St. Louis, USA), 
and antibodies against YY1 and other tags were from Santa 
Cruz Biotechnology (California, USA). 
1.3  Reporter assay, immunoprecipitation and im-
munoblotting 
Reporter assay, immunoprecipitation and immunoblotting 
were performed as previously described [39]. Reporter as-
says were performed in triplicate, and the data are presented 
as mean±standard deviations (SD) after normalization to 
Renilla-luciferase activity.  
1.4  RNA isolation and quantitative RT-PCR 
Total RNA extraction from cultured monolayer cells and 
quantitative reverse transcription-PCR (RT-PCR) were per-
formed as previously reported [40,41]. The primers used 
were as follows: for human GAPDH (glyceraldehyde-3- 
phosphate dehydrogenase), 5′-ACCACAGTCCATGCCA- 
TCAC-3′ and 5′-TCCACCACCCTGTTGCTGTA- 3′; for 
PAI-1, 5′-GAGACAGGCAGCTCGGATTC-3′ and 5′-GG- 
CCTCCCAAAGTGCATTAC-3′; for FURIN, 5′-CCTG- 
GTTGCTATGGGTGGTAG-3′ and 5′-AAGTGGTAATA- 
GTCCCCGAAGA-3′; for INHBE, 5′-ATCTTCCGATGG- 
GGACCAAG-3′ and 5′-AGAGTTAAGGTATGCCAGC- 
CC-3′; for SnoN, 5′-AGAGACTCTGTTTGCCCCAAGT-3′ 
and 5′-CATGCTAAACTTCTCCTTCATTTC-3′; and for 
FST, 5′-ACGTGTGAGAACGTGGACTG-3′ and 5′-C- 
ACATTCATTGCGGTAGGTTTTC-3′. Gene expression 
was normalized against GAPDH mRNA. Each sample was 
measured in triplicate experiments. Data were analyzed us-
ing Microsoft Excel software. 
1.5  Lentivirus production and infection 
The coding sequences (CDS) of GFP, Smad7 and YY1 were 
cloned into pENTR1A plasmid and LR clonase reactions 
(Invitrogen, USA) were carried out to place these CDS un-
der the control of CMV promoter in the p2k7neo lentiviral 
backbone (a gift from Dr. Kehkooi Kee, Tsinghua Univer-
sity) [42]. To produce defective lentivirus, we transfected 
293FT cells using Lipofectamine 2000 with the above re-
combinant lentivirus construct, pCMV∆8.9 and pMD.G 
(VSVG), at a ratio of 1:1.5:1. The culture supernatants 
were collected at 3 days post-transfection, and viral parti-
cles were concentrated by centrifugation. Hep3B cells were 
infected with lentivirus particles in the presence of 
polybrene (final concentration of 9 μg mL1, Sigma). Two 
or three days later, infection efficiency was examined on the 
basis of GFP expression and immunoblotting. For GFP- and 
Smad7-stable cell line establishment, G418 (250 μg mL1 
for final concentration; Invitrogen, California, USA) was 
added into culture media for 5 d to select cells with stable 
viral integration. 
2  Results 
2.1  YY1 is a novel binding partner of Smad7 
Smad7 plays a crucial role in balancing TGF-β signaling via 
negative feedback loops [14]. In order to explore how 
Smad7 activity is controlled, we searched for its interacting 
proteins. GST (glutathione S-transferase)-tagged Smad7 
was overexpressed in HEK293T cells, and after GST 
pull-down, all the Smad7-associated proteins were subject-
ed to SDS-PAGE gel analysis followed by mass spectro-
metric identification of Smad7-bound proteins. The nuclear 
transcription factor YY1 was identified. To verify their in-
teraction, we introduced constructs encoding HA-tagged 
YY1 and various Myc-tagged Smads into 293FT cells. At 
40 h post-transfection, the cells were lysed and subjected to 
anti-HA immunoprecipitation followed by anti-Myc im-
munoblotting. In accordance with previous report [37], YY1 
immunoprecipitated all the tested R-Smads, Smad4, and 
also the two inhibitory Smads, Smad6/7 (Figure 1A). Inter-
action of YY1 with Smad6/7 seemed to be stronger than 
those with R-Smads or Smad4 after normalizing the total 
protein levels. Smad7 is also associated with YY1 at the 
endogenous level in 293FT (Figure 1B). Interestingly, their 
interaction was attenuated by TGF-β1 treatment, implying 
that this interaction is regulated by TGF-β signaling.  
To consolidate the above phenomenon, we tested the in-
teraction of ectopic YY1 and Smad7 in the presence or ab-
sence of constitutively active form of TGF-β type I receptor 
ca-TβRI/ALK5, which is able to activate R-Smads and elicit 
signal transduction [43]. The immunoprecipitation result 
showed that YY1-Smad7 interaction was apparently weaker 
when ca-TβRI was co-expressed (Figure 1C), and similar 
result was obtained when a constitutively active BMP type I 
receptor ca-BMPRIB/ALK6 was co-transfected along with 
YY1, Smad6 or Smad7 (Figure 1D). The reverse immuno-
precipitation assay gave rise to the consistent results (Figure 
1E). These results clearly demonstrate that binding of YY1 
to I-Smads is negatively regulated by TGF-β or BMP sig-
naling. The N-terminal region and the conserved C-terminal 
MH2 domain of Smad7 could exert different effects in pro-
tein interaction or signaling regulation, thus we continued to 
determine which domain is responsible for Smad7 interac-
tion with YY1. As shown in Figure 1F, YY1 is mainly as-
sociated with the MH2 domain of Smad7. 
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Figure 1  Smad7 interacts with YY1. A, YY1 associates with Smad proteins. HA-YY1 and Myc-Smad constructs were transfected into 293FT cells. At  
40 h post-transfection, cells were lysed in TNE buffer and cell lysates were subjected to anti-HA immunoprecipitation (IP) followed by anti-Myc immunob-
lotting (IB), and protein expression in whole cell lysates (WCL) was examined by immunoblotting using antibodies against Myc- and HA-tags respectively. 
B, Endogenous interaction between Smad7 and YY1. Confluent 293FT cells were treated with or without 100 pmol L1 TGF-β1 for 2 h. Then cells were 
lysed for IP using anti-Smad7 antibody or control rabbit IgG and anti-YY1 immunoblotting. CE, TGF-β and BMP signaling attenuates the Smad7-YY1 
interaction. Various constructs were introduced into 293FT cells as indicated, and immunoprecipitation and immunoblotting were carried out as in Figure 1A. 
F, Domain mapping of Smad7. The experiment was done as in Figure 1A. 1259, the N-terminal region of Smad7 spanning amino acids (aa) 1259; MH2, 
the MH2 domain of Smad7 (260426 aa). 
2.2  YY1 cooperates with Smad7 to inhibit TGF-β-  
induced transcriptional responses 
Smad7 is well documented to antagonize TGF-β signaling, 
and YY1 was also reported to inhibit TGF-β-induced tran-
scription by associating with R-Smads and Smad4 [37]. The 
identification of the YY1-Smad7 association prompts us to 
ask whether the two proteins could cooperate with one an-
other to negatively regulate TGF-β signaling. To address 
this question, we first performed reporter assays in 293FT 
cells using the CAGA-luciferase reporter, which contains 
repeated canonical Smad binding elements (SBE) and re-
sponds to TGF-β quite specifically [44]. As shown in Figure 
2A, various amounts of Smad7- or YY1-expression con-
structs were transfected together with CAGA-luciferase 
reporter and the control Renilla plasmid. Both Smad7 and 
YY1 inhibited TGF-β-stimulated reporter expression in 
dose-dependent manners, and Smad7 seemed to be more 
effective in this respect. Then we transfected low amounts 
of Smad7 or YY1 constructs alone or together and carried 
out reporter assay experiment. Although Smad7 or YY1 
alone decreased TGF-β-triggered transcriptional responses 
to a certain degree, co-expression of the two proteins led to 
a dramatic inhibition (Figure 2B), indicating that YY1 could 
cooperate with Smad7 to inhibit TGF-β-elicited transcrip-
tion. 
To confirm the cooperative effect between Smad7 and 
YY1 at the endogenous level, shRNA targeting Smad7 and 
siRNAs targeting human YY1 were used. Two of the three 
siRNAs (si-1 and si-3) designed showed high efficiency in 
knocking down YY1 expression (Figure 2C). Knockdown 
of YY1 alleviated the inhibitory effects of Smad7 to some 
extent, while silence of Smad7 attenuated the inhibitory 
effects of YY1 on TGF-β signaling (Figure 2D).  
2.3  YY1 synergizes with nuclear Smad7 and facilitates 
its transcription repression activity 
Both YY1 and Smad7 are reported as primarily nuclear 
proteins [20,31], and this was confirmed in Hep3B hepato-
cellular carcinoma cells by immunofluorescence (data not 
shown). We reasoned that they may physically associate 
and functionally synergize in the nucleus. To examine this, 
we compared the synergy between YY1 and wild-type 
Smad7 or nuclear localization signal (NLS)-tagged Smad7, 
which is completely localized in the nucleus when ex-
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Figure 2  Smad7 and YY1 cooperate with one another to inhibit TGF-β/Smad-driven transcriptional responses. A, Smad7 and YY1 antagonize 
TGF-β/Smad-driven CAGA-luciferase reporter expression in a dose-dependent manner. One day after plating of 293FT cells into 24-well plates, different 
amounts of Smad7 and YY1 constructs were transfected along with the CAGA-luciferase reporter (200 ng per 3 wells, the same for below) and Renilla- 
luciferase plasmid (20 ng). After 20 h, the cells were treated with 100 pmol L1 TGF-β1 overnight and harvested for luciferase activity measurement as de-
scribed in Materials and methods. B, Smad7 cooperates with YY1 to inhibit TGF-β signaling. Plasmids encoding Smad7 (5 and 10 ng), YY1 (10 and 25 ng), 
CAGA-luciferase (200 ng) and Renilla-luciferase (20 ng) were transfected into 293FT cells as indicated. C, GFP-expression plasmid, non-specific (NS-) 
siRNA or YY1-targeting siRNAs were transfected into 293FT cells using Lipofactamine 2000. Endogenous YY1 expression level was detected by im-
munoblotting. Tubulin was detected as loading controls. D, Both Smad7 and YY1 are required for efficient repression of TGF-β signaling. Plasmids encod-
ing YY1 (25 and 50 ng), Smad7 (25 and 50 ng), Smad7 shRNA (100 ng) or GFP-targeting shRNA (100 ng), NS-siRNA (100 ng) or YY1-specific siRNAs 
(100 ng) were transfected into 293FT cells for CAGA-luciferase reporter assay. **, P<0.01. 
pressed in cells [20]. Indeed, CAGA-luciferase reporter 
assay in Hep3B cells revealed that NLS-Smad7 also worked 
together with YY1 in antagonizing TGF-β-induced tran-
scriptional responses, as effective as that of wild-type 
Smad7 (Figure 3A), strongly suggesting that it is nuclear 
Smad7 that collaborates with YY1. 
As a transcription factor/co-factor, YY1 and Smad7 can 
associate with histone deacetylases (HDACs) and regulate 
gene expression [22,24,31,32]. Therefore, we asked whether 
HDACs are involved in the synergy between YY1 and 
Smad7 in attenuating TGF-β signaling. As a typical member, 
HDAC1 was reported to associate with both Smad7 and 
YY1 [22,31] (also our unpublished data), thus was tested 
here. First, we examined whether Smad7 could affect the 
association of YY1 with HDAC1. As shown in Figure 3B, 
YY1 immunoprecipitated both HDAC1 and Smad7, and 
co-expression of Smad7 strengthened the YY1-HDAC1 
interaction. As Smad7 has been shown to possess transcrip-
tion suppression ability using Gal4-luciferase reporter assay 
[45] (also our unpublished data), we determined whether 
YY1 or HDAC1 could facilitate Smad7. Expression of 
Gal4-DBD-fused Smad7 alone decreased the Gal4-TK-  
luciferase reporter expression to a certain degree, while 
co-expression of YY1 and/or HDAC1 further reinforced 
Smad7’s effect (Figure 3C), implying that YY1 and 
HDAC1 could facilitate Smad7’s function as a transcrip-
tional co-repressor. Functionally, HDAC1 was able to at-
tenuate TGF--induced CAGA-luciferase reporter expres-
sion moderately when expressed alone, and its co-expres- 
sion with Smad7 and YY1 led to a dramatic inhibition of 
TGF- signaling (Figure 3D). 
2.4  Smad7 inhibits TGF-β-induced gene expression in 
Hep3B cells in cooperation with YY1 
Having established that YY1 cooperates with nuclear 
Smad7 to inhibit TGF-β-stimulated transcriptional respons-
es, we wondered whether this cooperation is significant in 
vivo by examining TGF-β target gene expression in Hep3B 
cells. Hep3B cells with stable expression of GFP or Smad7 
were infected with or without YY1-expression virus. Three 
days later, the cells were harvested to detect Smad7 and 
YY1 expression by immunoblotting (Figure 4A). Then par-
allel samples were treated with or without TGF-β1 for 4 h 
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Figure 3  YY1 coordinates with nuclear Smad7 and facilitates its transcription repression activity. A, YY1 coordinates with nuclear Smad7 in antagonizing 
TGF-β signaling. CAGA-luciferase reporter assay was performed as Figure 2A in Hep3B cells. YY1 (10 and 25 ng) and Smad7 plasmids were transfected as 
indicated. B, Smad7 enhances YY1 association with HDAC1. IP experiment was done as in Figure 1A in 293FT cells. C, YY1 and HDAC1 facilitate the 
transcription suppression activity of Smad7. 293FT cells transfected with Gal4-TK-luciferase (200 ng), Renilla (20 ng), Smad7 (100 ng), YY1 (100 ng) or 
HDAC1 (100 ng) plasmids were subjected to reporter assay and luciferase activity determination. DBD, DNA binding domain of Gal4. *, P<0.05; **, 
P<0.01. D, HDAC1 promotes the inhibitory effects of Smad7 and YY1 on TGF-β signaling. CAGA-luciferase reporter assay was performed in Hep3B cells. 
Plasmids encoding Smad7 (5 ng), YY1 (5 ng) and HDAC1 (25 and 50 ng) were transfected as indicated. *, P<0.05; **, P<0.01. 
and harvested for total RNA extraction and gene expression 
analysis. As shown in Figure 4B, Smad7 or YY1 alone in- 
hibited expression of several typical TGF-β target genes, 
including PAI-1, FURIN, INHBE, SnoN and FST, and 
co-expression of Smad7 and YY1 further attenuated their 
expression.  
3  Discussion 
TGF-β/Smad signaling is delicately modulated by numerous 
regulators in both positive and negative manners [25,13]. 
Two inhibitory Smads, Smad6/7, have been well established 
as crucial regulators for TGF-β superfamily pathways via 
negative feedback loops [14]. Smad7 is a general antagonist 
for the TGF-β superfamily, while Smad6 is more specifi-
cally involved in the BMP pathways. Since its first cloning 
and characterization in 1997, Smad7 has been extensively 
studied [46,47]. Gene-targeting and transgenic studies using 
mouse models have firmly established the crucial roles of 
Smad7 in embryonic development and adult tissue homeo-
stasis by modulating TGF-β signaling [1518]. Knockout of 
Smad7 in mice leads to embryonic lethality or death a few 
days after birth, depending on gene targeting strategies and 
mouse background. Smad7-deficient mice showed enhanced 
phospho-Smad2/3 level in cardiac tissues, B cells or T cells, 
indicative of augmented TGF-β signaling. Moreover, altered 
expression of Smad7 has been found to be closely related to 
several human diseases, such as tumorigenesis, scleroderma 
and chronic inflammatory bowel disease (IBD) [14,15]. 
Smad7 was first found to form stable complex with 
TGF-β receptors upon TGF-β stimulation, inhibiting 
Smad2/3 recruitment to the receptors and subsequent acti-
vation [46,47]. Smad7 can recruit WW-HECT type E3 
ubiquitin ligases (such as Smurf1, Smurf2, NEDD4-2 or 
WWP1) to activated TβRI, resulting in polyubiquitination 
and degradation, or the phosphatase GADD34-PP1c to 
dephosphorylate and inactivate the receptor [14,19]. Fur-
thermore, we have extended Smad7’s role by finding that it 
also impedes TGF-β/Smad-induced transcriptional respons-
es in the nucleus [20,21]. Recent studies further emphasized 
the importance of nuclear Smad7 in regulating gene expres-
sion by acting as a co-repressor or co-activator [2426]. 
However, the regulatory mechanisms for nuclear Smad7  
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Figure 4  YY1 and Smad7 collaborate with one another to inhibit TGF-β 
target gene expression. A, Expression of YY1 and Smad7 in Hep3B cells. 
Hep3B cells stably expressing Smad7 were transiently infected with 
YY1-expression viruses and cultured for 3 d, and analyzed by immunob-
lotting. B, Parallel cell samples in Figure 4A were treated with or without 
100 pmol L1 TGF-β1 for 4 h before harvested to extract total RNA for 
gene expression analysis as described in Materials and methods. *, P<0.05; 
**, P<0.01. 
remain largely unknown. In this study, we found that YY1 
was a novel binding partner of Smad7. Overexpression of 
the two proteins inhibited the TGF-β/Smad-induced tran-
scriptional responses in a collaborative manner in both re-
porter assay and in TGF-β target gene expression. In addi-
tion, knockdown of endogenous Smad7 alleviated the inhib-
itory effects of YY1 on TGF-β signaling, while silence of 
YY1 decreased Smad7’s effects to a certain degree, imply-
ing that the inhibitory function of YY1 on TGF-β signaling 
is dependent on Smad7 to some extent. Interestingly, we 
noticed that the YY1-Smad7 interaction is attenuated by 
TGF-β treatment, suggesting that their association is sig-
naling-controlled, and could be more significant by acting 
as a safeguard to prevent basal expression of TGF-β targets. 
YY1 is a nuclear transcription factor involved in cell 
growth, differentiation and embryonic development by reg-
ulating related gene expression [3032]. Smad7 is also pri-
marily a nuclear factor, although it may enter the cytoplasm 
upon TGF-β treatment, dependent on cell types or cell lines 
[14,20]. Thereby we proposed that YY1 and Smad7 collab-
orate in the nucleus. Indeed, functional assays showed that 
NLS-Smad7 is as effective as wild-type Smad7 in syner-
gizing with YY1 and antagonizing TGF-β-stimulated re-
porter expression. As NLS-Smad7 is completely localized 
in the nucleus when introduced into cells [20], the above 
results absolutely support their collaboration in the nucleus. 
Besides acting as a transcription factor, YY1 can also 
regulate gene expression without its DNA binding activity, 
by functioning as a co-factor and recruiting other regulators 
[30,32]. In this regard, the physical interactions between 
YY1 and R-Smads or Smad4 were found to interfere with 
Smad-DNA binding, impeding Smad transcriptional activi-
ties [37]. Similarly, the CAGA-luciferase and Gal4-TK- 
luciferase reporters used in this study do not have the bind-
ing element for YY1 neither, thus YY1 is likely to syner-
gize with Smad7 through physical interactions. Mechanisti-
cally, YY1 can interact with HDAC1 and Smad7 simulta-
neously (Figure 3B), implying that they may form a ternary 
complex; Smad7 is capable of promoting the YY1-HDAC1 
association. Furthermore, YY1 and HDAC1 reinforced the 
transcription repression ability of Smad7 in Gal4-luciferase 
reporter assay. HDAC1 is capable of removing acetyl 
groups from histones, resulting in a more compact confor-
mation of histones and shutdown of gene expression in the 
vicinity. Therefore, Smad7 and YY1 could act as transcrip-
tional co-repressors to inhibit expression of TGF-β target 
genes. Previous studies showed that Smad7 probably binds 
DNA elements similar to those of R-Smads or Smad4-  
activin responsive element (ARE) in vitro and the Smad 
binding element (SBE) in PAI-1 promoter in vivo [20,21]. 
Although the DNA binding ability of YY1 is not required 
for inhibiting R-Smads/Smad4-dependent gene expression, 
or for synergy with Smad7 in antagonizing the canonical 
TGF-β/Smad signaling, we do not exclude the possibility 
that the DNA binding abilities of YY1 and Smad7 may play 
a role in regulating genes other than TGF-β targets. 
In summary, our results together with previous reports 
suggest that Smad7 and YY1 could take use of different but 
related mechanisms to antagonize TGF-β/Smad signaling in 
the nucleus. First, they interfere with functional Smad-DNA 
complex formation; second, they act as transcriptional 
co-repressors and inhibit expression of TGF-β target genes 
synergistically by recruiting HDAC1. This newly found 
cooperative nature of Smad7 and YY1 could play a crucial 
role in controlling basal expression of TGF-β targets. As 
critical negative regulators, Smad7 could inhibit TGF-β/ 
Smad-induced cellular functions such as cell cycle arrest, 
cell differentiation and apoptosis, and YY1 was also able to 
block TGF-β/Smad-elicited cell differentiation [14,15,37]. 
Therefore, the functional consequences of Smad7 and YY1 
cooperation in antagonizing TGF-β/ Smad-induced cellular 
actions remain an open question and deserve further studies. 
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